The Generic Pharmaceutical Association (GPhA) announced its 2015 executive committee and board of directors on Monday.
Craig Wheeler, president and CEO of Momenta Pharmaceuticals, was re-elected as GPhA board chairman.
The remainder of the 2015-2016 GPhA board of directors includes: Debra Barrett, Teva Americas; Doug Boothe, Perrigo Company; Chuck Caprariello, Ranbaxy, Inc.; John Ducker, Fresenius-Kabi; Jeff Glazer, Heritage Pharmaceuticals; Peter Goldschmidt, Sandoz US; Marcy Macdonald, Impax Laboratories; Marcie McClintic Coates, Mylan, Inc.; Paul McGarty, Lupin Pharmaceuticals; Chirag Patel, Amneal Pharmaceuticals; Tony Pera, Par Pharmaceuticals; Julie Reed, Hospira, Inc.; Joseph Renner, Zydus Pharmaceuticals, Inc. and Jeff Watson, Apotex Corporation
GPhA fills 86 percent of U.S. prescriptions, but only uses 27 percent of total drug spending. Over the past 10 years, generic medicines have saved the U.S. system $1.46 trillion with $239 billion saved in 2013 alone, according to a report conducted for the GPhA by the IMS Institute for Healthcare Informatics.
“The generic drug industry is growing and is stronger than ever,” Wheeler said. “GPhA members play a critical role in our nation’s health system — providing safe, effective, more affordable generic drugs for millions of people. I am extremely excited to continue to chair GPhA, seize the exciting opportunities ahead and usher in a new era of affordable medicine, particularly as we come closer to the day when the first biosimilars become available in the United States.”
Alerts Sign-up